Landos Biopharma, Inc. (LABP) Stock Analysis
DELISTED 2024
What happened to Landos Biopharma, Inc. (LABP) stock?
Landos Biopharma, Inc. (LABP) no longer trades on public markets. It was delisted in May 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Landos Biopharma, Inc. (LABP) trades at $22.93. Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for autoimmune diseases. Market cap: $71.7M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for LABP: LABP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LABP against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
LABP: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Landos Biopharma, Inc. (LABP) Healthcare & Pipeline Overview
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in oral therapeutics for autoimmune diseases, with a focus on gut-restricted and systemically bioavailable small molecules. Their lead candidate, omilancor, targets LANCL2 for the treatment of ulcerative colitis, Crohn's disease, and eosinophilic esophagitis, positioning them in a competitive biotechnology landscape.
What Is the Investment Thesis for LABP?
Landos Biopharma, Inc. presents a compelling investment thesis centered on its innovative pipeline of oral therapeutics targeting autoimmune diseases. The company's lead candidate, omilancor, has the potential to address a significant market in ulcerative colitis, Crohn's disease, and eosinophilic esophagitis. A successful clinical trial outcome for omilancor could drive substantial value. The company's market capitalization is approximately $0.07 billion as of 2026-03-16. Key risks include clinical trial failures and competition from established pharmaceutical companies. The company's P/E ratio is -6.56, reflecting its current lack of profitability. Positive clinical data and strategic partnerships could serve as major catalysts for growth.
Based on FMP financials and quantitative analysis
LABP Key Highlights
Market capitalization of $71.7M indicates the company's current valuation in the market.
- P/E ratio of -6.56 reflects the company's current lack of profitability due to ongoing research and development expenses.
- Lead product candidate, omilancor, targets a significant market in ulcerative colitis, Crohn's disease, and eosinophilic esophagitis.
- The company's pipeline includes multiple preclinical candidates targeting a range of autoimmune diseases.
- Beta of 0.14 suggests lower volatility compared to the overall market.
Who Are LABP's Competitors?
LABP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACHL Achilles Therapeutics plc | $1.48 | +0.68% | $60.8M | 47 |
| BLI Berkeley Lights, Inc. | $1.20 | -5.88% | $86.6M | 51 |
| HTBX Heat Biologics, Inc. | $2.38 | +0.42% | $61.1M | 48 |
| IGMS IGM Biosciences, Inc. | $1.27 | +0.00% | $77.5M | 60 |
| JBIO Jade Biosciences, Inc. | $21.23 | -5.85% | $1.29B | 61 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LABP's Key Strengths?
Novel oral therapeutics for autoimmune diseases
- Targeting specific pathways like LANCL2 and NOD-like receptor X1
- Strong intellectual property portfolio
- Experienced management team
What Are LABP's Weaknesses?
Clinical-stage company with no approved products
- High research and development costs
- Reliance on successful clinical trial outcomes
- Limited financial resources
What Could Drive LABP Stock Higher?
LABP catalyst: Data readout from ongoing clinical trials of omilancor in ulcerative colitis, Crohn's disease, and eosinophilic esophagitis.
- Initiation of clinical trials for LABP-104 in systemic lupus erythematosus and rheumatoid arthritis.
- Progress in preclinical development of LABP-66, LABP-69, LABP-73, and LABP-111.
- Potential for strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for LABP?
Financial-distress signal — its Altman Z-Score of -3.23 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-61.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for omilancor or other product candidates.
- Competition from established pharmaceutical companies with approved autoimmune disease therapies.
- Regulatory delays or rejection of product candidates.
- Patent expirations and intellectual property challenges.
- High research and development costs.
What Are the Growth Opportunities for LABP?
- Omilancor's Clinical Development: The successful advancement of omilancor through clinical trials represents a significant growth opportunity for Landos Biopharma. Positive Phase 3 data in ulcerative colitis, Crohn's disease, or eosinophilic esophagitis could lead to regulatory approval and commercialization. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
- Expansion of Pipeline: Landos Biopharma's preclinical pipeline offers several growth opportunities. The development of LABP-104 for systemic lupus erythematosus and rheumatoid arthritis could expand the company's reach into additional autoimmune indications. Similarly, LABP-66, LABP-69, LABP-73, and LABP-111 target other diseases, including multiple sclerosis, Alzheimer's disease, diabetic nephropathy, asthma, chronic obstructive pulmonary disease, nonalcoholic steatohepatitis and type 1 diabetes. Timeline: Preclinical development ongoing with potential clinical trials in the next 2-3 years.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of Landos Biopharma's product candidates. These partnerships could provide funding, expertise, and access to broader markets. Collaborations could also involve licensing agreements or joint development programs. Timeline: Ongoing discussions with potential partnerships in the next 1-2 years.
- Targeting LANCL2 Pathway: Landos Biopharma's focus on the LANCL2 pathway represents a unique growth opportunity. LANCL2 is a novel target with potential applications in multiple autoimmune diseases. Further research into the LANCL2 pathway could lead to the discovery of additional therapeutic candidates. Timeline: Ongoing research with potential for new discoveries in the next 3-5 years.
- Oral Therapeutics Market: The increasing preference for oral therapeutics over injectable or infused therapies creates a favorable environment for Landos Biopharma's oral drug candidates. Oral drugs offer convenience and ease of administration, which can improve patient compliance and outcomes. The market for oral autoimmune disease therapies is expected to grow significantly in the coming years. Timeline: Ongoing trend with increasing adoption of oral therapies.
What Are LABP's Competitive Advantages?
- Proprietary oral drug formulations
- Targeting novel pathways like LANCL2 and NOD-like receptor X1
- Strong intellectual property portfolio
- Experienced management team
What Does LABP Do?
Landos Biopharma, Inc., founded in 2017 and headquartered in Blacksburg, Virginia, is a biopharmaceutical company dedicated to discovering and developing innovative oral therapeutics for patients suffering from autoimmune diseases. The company's core strategy revolves around targeting specific pathways within the body to modulate the immune system and alleviate the symptoms associated with these chronic conditions. Landos Biopharma's lead product candidate, omilancor, is a gut-restricted oral therapeutic that targets lanthionine synthetase C-like protein 2 (LANCL2). Omilancor is currently in development for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis. In addition to omilancor, Landos Biopharma is also developing NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD. Furthermore, LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA), is also in their pipeline. The company's preclinical pipeline includes LABP-66 for multiple sclerosis and Alzheimer's disease, LABP-69 for diabetic nephropathy and RA, LABP-73 for asthma and chronic obstructive pulmonary disease, and LABP-111 for nonalcoholic steatohepatitis and type 1 diabetes. Landos Biopharma aims to provide convenient and effective oral therapies for patients with autoimmune diseases, addressing significant unmet medical needs.
What Products and Services Does LABP Offer?
- Develop oral therapeutics for autoimmune diseases
- Target lanthionine synthetase C-like protein 2 (LANCL2)
- Develop treatments for ulcerative colitis (UC)
- Develop treatments for Crohn's disease (CD)
- Develop treatments for eosinophilic esophagitis
- Develop treatments for systemic lupus erythematosus and rheumatoid arthritis (RA)
- Develop treatments for multiple sclerosis and Alzheimer's disease
- Develop treatments for diabetic nephropathy, asthma, chronic obstructive pulmonary disease, nonalcoholic steatohepatitis and type 1 diabetes
How Does LABP Make Money?
- Discover and develop novel oral therapeutics
- Conduct preclinical and clinical trials
- Seek regulatory approval for product candidates
- Commercialize approved products or partner with larger pharmaceutical companies
What Industry Does LABP Operate In?
Landos Biopharma operates within the competitive biotechnology industry, focusing on autoimmune disease therapeutics. The market for autoimmune disease treatments is substantial and growing, driven by an increasing prevalence of these conditions and advancements in understanding their underlying mechanisms. Competition includes established pharmaceutical companies and other biotech firms developing novel therapies. Landos Biopharma differentiates itself through its focus on oral therapeutics and specific targets like LANCL2 and NOD-like receptor X1. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and the potential for significant returns on successful products.
Who Are LABP's Key Customers?
- Patients with autoimmune diseases
- Healthcare providers
- Pharmaceutical companies (potential partners)
Insider Activity
The most recent 12 insider filings for Landos Biopharma, Inc. break down as 12 sales and 0 purchases. On net that is roughly 25K shares disposed (about $174K), a signal worth weighing alongside the fundamentals.
LABP Valuation & Market Position
With a $71.7M market cap, Landos Biopharma, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for Landos Biopharma, Inc. stands at -61.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -57.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -28.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Landos Biopharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.23 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Landos Biopharma, Inc. revenue of about $1.0M for fiscal 2026, with EPS near $-1.19.
Company Profile
Landos Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Blacksburg, US. The company is led by CEO Gregory Oakes. LABP has traded publicly since 2021.
LABP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in LABP's future, indicating that key stakeholders see potential upside.
- Community sentiment has shifted positively with increasing discussions around LABP's innovative treatments, reflecting growing enthusiasm.
- Recent partnerships and collaborations in the biotech sector have positioned LABP favorably among peers, enhancing its credibility.
- Upcoming clinical trial results are anticipated, which could catalyze interest and investment if outcomes are promising.
Bear Case
- Market perception remains cautious due to the inherent risks associated with biotech stocks, particularly those in early-stage development.
- Negative sentiment has emerged from recent delays in regulatory approvals, causing concern among investors about LABP's timeline.
- Some analysts express skepticism over the scalability of LABP's technologies, raising doubts about long-term profitability.
- Community discussions have highlighted a lack of clear communication from management, leading to uncertainty and mistrust among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LABP Latest News
No recent news available for LABP.
Leadership: Gregory Oakes
CEO
Gregory Oakes serves as the CEO of Landos Biopharma, bringing extensive experience in the biotechnology industry. His background includes leadership roles in various pharmaceutical and biotech companies, where he focused on drug development, commercialization, and strategic partnerships. He has a proven track record of building and managing successful teams. Oakes is responsible for overseeing Landos Biopharma's overall strategy, operations, and financial performance.
Track Record: Under Gregory Oakes' leadership, Landos Biopharma has advanced its lead product candidate, omilancor, through clinical trials. He has also overseen the expansion of the company's pipeline and the formation of strategic partnerships. His focus has been on driving innovation and creating value for shareholders.
What Investors Ask About Landos Biopharma, Inc. (LABP) — Healthcare
What happened to Landos Biopharma, Inc. (LABP) stock?
Landos Biopharma, Inc. (LABP) no longer trades on public markets. It was delisted in May 2024. The figures below are historical and are not a current quote.
Can I still buy LABP shares?
No. LABP stopped trading on public markets in May 2024, so the shares are not available through a broker. Anything you see quoted for LABP elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before LABP stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Landos Biopharma, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Landos Biopharma, Inc. do?
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral therapeutics for autoimmune diseases. Their lead product candidate, omilancor, is a gut-restricted oral therapeutic targeting lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis, Crohn's disease, and eosinophilic esophagitis.
What are the main risks for LABP?
The main risks for Landos Biopharma, Inc. include the inherent uncertainties of clinical drug development. Clinical trial failures or delays could significantly impact the company's value. Competition from established pharmaceutical companies with approved autoimmune disease therapies also poses a risk. Regulatory hurdles and potential patent expirations could also affect the company's prospects. Additionally, the company's reliance on external funding and strategic partnerships exposes it to financial and operational risks.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending for LABP.